
3M Settles PFAS Claims With New Jersey In Landmark $450 Million Agreement
3M’s settlement with New Jersey signals a new phase in PFAS enforcement. With liabilities extending decades and across industries, the case serves as a critical benchmark for regulatory, legal, and commercial strategies in managing PFAS risk.
Published in June 2025. Dates, deadlines and stages may have changed since.
2 min readAI-drafted, expert reviewed

3M has agreed to a landmark settlement with the State of New Jersey to resolve longstanding liabilities related to per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals”. Announced in May 2025, the deal is valued at up to $450 million (£355 million) and represents the largest statewide PFAS agreement in New Jersey’s history. For industry professionals, this development underscores intensifying legal and regulatory pressures linked to PFAS use and legacy contamination.
Background: PFAS Regulation And Corporate Liability
The agreement covers claims dating back to 2019, including environmental damage at the Chambers Works and Parlin sites, as well as liabilities stemming from PFAS in aqueous film-forming foam (AFFF). 3M’s own release values the settlement at a present value of $285 million (£225 million), structured over a 25-year payment schedule. The State’s higher figure reflects total projected disbursements including punitive damages and project-specific remediation funding.
PFAS are synthetic substances widely used since the 1940s in non-stick cookware, textiles, and firefighting foams. Their chemical stability makes them resistant to degradation, allowing accumulation in the environment and human body. Scientific studies have linked PFAS exposure to serious health effects, including cancer and endocrine disruption.
Impacts Across The Chemicals And Manufacturing Sectors
The settlement has far-reaching implications for stakeholders across the chemicals value chain. In addition to financial risks, the case sets a precedent for state-level accountability beyond federal regulatory frameworks. Companies involved in the manufacture, use, or sale of PFAS-containing products may face increased scrutiny and compliance obligations.
Notably, the agreement spares 3M from a trial set for May 19, 2025, and releases the firm from future liability linked to PFAS contamination in New Jersey. The company has also reaffirmed its plan to end all PFAS manufacturing by the end of 2025, aligning with broader regulatory and market shifts towards safer chemical alternatives.
Official source
prnewswire.comTopics
Questions about this change
What does 3M’s PFAS settlement with New Jersey mean for other manufacturers?
It highlights the escalating legal exposure linked to PFAS. Companies across the manufacturing chain should review past and current uses of PFAS in their products and prepare for similar claims or regulatory actions.
Why are PFAS chemicals under such intense scrutiny?
PFAS are persistent, bioaccumulative, and toxic. Their link to cancer and environmental harm has led to increasing regulatory action, including use restrictions, reporting obligations, and litigation aimed at clean-up and compensation.

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanFind out what this means for your products
Foresight follows changes like this one and shows where they reach your substances, products and markets.
- PFAS portfolio reviewWhere PFAS sit in your products, under each definition that applies.
- Substitution screeningAlternatives to a substance of concern, checked for their own hazards and restrictions.
- Regulatory horizon scanningAlerts scored for your organisation, most important first.
Join 3,500+ professionals staying ahead
Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at

